原发性醛固酮增多症的诊治现状及展望

doi:10.16150/j.1671-2870.2020.05.001

摘要/Abstract

关键词: 原发性醛固酮增多症, 醛固酮/肾素比值, 静脉生理盐水滴注试验, 卡托普利试验

中图分类号:

R544.1

蒋怡然, 王卫庆. 原发性醛固酮增多症的诊治现状及展望[J]. 诊断学理论与实践, 2020, 19(05): 445-449.

参考文献 29

[1]	Monticone S, Burrello J, Tizzani D, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice[J]. J Am Coll Cardiol, 2017, 69(14):1811-1820. doi: S0735-1097(17)30569-7 pmid: 28385310
[2]	中华医学会内分泌学分会. 原发性醛固酮增多症诊断治疗的专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9):727-736.
[3]	Sang X, Jiang Y, Wang W, et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China[J]. J Hypertens, 2013, 31(7):1465-1471. doi: 10.1097/HJH.0b013e328360ddf6 URL
[4]	Xu Z, Yang J, Hu J, et al. Primary aldosteronism in patients in China with recently detected hypertension[J]. J Am Coll Cardiol, 2020, 75(16):1913-1922.
[5]	Hu Y, Zhang J, Liu W, et al. Determining the prevalence of primary aldosteronism in patients with new-onset type 2 diabetes and hypertension[J]. J Clin Endocrinol Metab, 2020, 105(4):dgz293.
[6]	Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients[J]. Arch Intern Med, 1981, 141(12):1589-1593. pmid: 7030245
[7]	Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline[J]. J Clin Endocrinol Metab, 2016, 101(5):1889-1916. doi: 10.1210/jc.2015-4061 pmid: 26934393
[8]	Burrello J, Monticone S, Buffolo F, et al. Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism[J]. J Hypertens, 2016, 34(5):920-977. doi: 10.1097/HJH.0000000000000880 pmid: 27031933
[9]	Glinicki P, Jeske W, Bednarek-Papierska L, et al. The ratios of aldosterone / plasma renin activity (ARR) versus aldosterone / direct renin concentration(ADRR)[J]. J Renin Angiotensin Aldosterone Syst, 2015, 16(4):1298-1305. doi: 10.1177/1470320313519487 URL
[10]	Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives[J]. J Intern Med, 2019, 285(2):126-148. doi: 10.1111/joim.12831 pmid: 30255616
[11]	宋颖, 何文雯, 杨淑敏, 等. 化学发光法测定血浆醛固酮浓度/肾素浓度比值筛查原发性醛固酮增多症的[J]. 中华内科杂志, 2016, 55(1):6-10.
[12]	Li Y, Liu Y, Li J, et al. Sodium infusion test for diagnosis of primary aldosteronism in chinese population[J]. J Clin Endocrinol Metab, 2016, 101(1):89-95. doi: 10.1210/jc.2015-2840 URL
[13]	Wang K, Hu J, Yang J, et al. Development and validation of criteria for sparing confirmatory tests in diagnosing primary aldosteronism[J]. J Clin Endocrinol Metab, 2020, 105(7):dgaa282.
[14]	Song Y, Yang S, He W, et al. Confirmatory tests for the diagnosis of primary aldosteronism: a prospective diagnostic accuracy study[J]. Hypertension, 2018, 71(1):118-124. doi: 10.1161/HYPERTENSIONAHA.117.10197 URL
[15]	陈适, 曾正陪, 宋爱羚, 等. 卡托普利试验在原发性醛固酮增多症诊断中的应用[J]. 中华内科杂志, 2017, 56(6):402-408.
[16]	Rossi GP, Auchus RJ, Brown M, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism[J]. Hypertension, 2014, 63(1):151-160. doi: 10.1161/HYPERTENSIONAHA.113.02097 URL
[17]	Ma D, Liu X, Zeng L, et al. The role of adrenal venous sampling and computed tomography in the management of primary aldosteronism[J]. J Hypertens. 2020-08-29 [2020/ 10/ 16]. https://pubmed.ncbi.nlm.nih.gov/32868641/.
[18]	Jiang Y, Zhang C, Wang W, et al. Diagnostic value of ACTH stimulation test in determining the subtypes of primary aldosteronism[J]. J Clin Endocrinol Metab, 2015, 100(5):1837-1844. doi: 10.1210/jc.2014-3551 URL
[19]	Küpers EM, Amar L, Raynaud A, et al. A clinical prediction score to diagnose unilateral primary aldosteronism[J]. J Clin Endocrinol Metab, 2012, 97(10):3530-3537. doi: 10.1210/jc.2012-1917 URL
[20]	Zhang Y, Niu W, Zheng F, et al. Identifying unilateral disease in Chinese patients with primary aldosteronism by using a modified prediction score[J]. J Hypertens, 2017, 35(12):2486-2492. doi: 10.1097/HJH.0000000000001488 pmid: 28708774
[21]	Xiao L, Jiang Y, Zhang C, et al. A novel clinical nomogram to predict bilateral hyperaldosteronism in Chinese patients with primary aldosteronism[J]. Clin Endocrinol (Oxf), 2019, 90(6):781-788. doi: 10.1111/cen.13962 URL
[22]	蒋怡然, 张翠, 姜蕾, 等. 螺内酯单药治疗及低剂量螺内酯联合治疗特发性醛固酮增多症的有效性及安全性[J]. 中华内分泌代谢杂志, 2018, 34(6):479-484.
[23]	Karagiannis A, Tziomalos K, Papageorgiou A, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism[J]. Expert Opin Pharmacother, 2008, 9(4):509-515. doi: 10.1517/14656566.9.4.509 pmid: 18312153
[24]	Amar L, Azizi M, Menard J, et al. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism[J]. Hypertension, 2010, 56(5):831-838. doi: 10.1161/HYPERTENSIONAHA.110.157271 URL
[25]	Bogman K, Schwab D, Delporte ML, et al. Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase(CYP11B2)[J]. Hypertension, 2017, 69(1):189-196. doi: 10.1161/HYPERTENSIONAHA.116.07716 URL
[26]	Zheng FF, Zhu LM, Nie AF, et al. Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma[J]. Hypertension, 2015, 65(3):622-628. doi: 10.1161/HYPERTENSIONAHA.114.03346 URL
[27]	Li X, Wang B, Tang L, et al. GSTA1 expression is correlated with aldosterone level in KCNJ5-mutated adrenal aldosterone-producing adenoma[J]. J Clin Endocrinol Metab, 2018, 103(3):813-823. doi: 10.1210/jc.2017-00950 URL
[28]	Cao Y, Zhou W, Li L, et al. Pan-cancer analysis of somatic mutations across 21 neuroendocrine tumor types[J]. Cell Res, 2018, 28(5):601-604. doi: 10.1038/s41422-018-0019-5 URL
[29]	Omata K, Satoh F, Morimoto R, et al. Cellular and gene-tic causes of idiopathic hyperaldosteronism[J]. Hypertension, 2018, 72(4):874-880. doi: 10.1161/HYPERTENSIONAHA.118.11086 pmid: 30354720

原发性醛固酮增多症的诊治现状及展望

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 29

相关文章 8

编辑推荐

Metrics

本文评价

[1]	陈歆, 程艾邦, 许建忠, 李燕, 王继光. 中国高血压患者原发性醛固酮增多症的前瞻性筛查研究进展[J]. 诊断学理论与实践, 2020, 19(05): 450-453.
[2]	中国高血压联盟. 高血压患者原发性醛固酮增多症筛查诊治流程[J]. 诊断学理论与实践, 2020, 19(05): 454-459.
[3]	程艾邦, 李明轩, 陈波, 曹晟, 蒋塨豪, 许建忠, 李燕, 王继光. 化学发光免疫分析法检测血浆肾素、醛固酮在原发性醛固酮增多症诊断中的价值[J]. 诊断学理论与实践, 2020, 19(05): 474-480.
[4]	胡哲, 陈歆, 罗芳秀, 初少莉, 王继光. 肾上腺醛固酮和皮质醇共分泌瘤一例报告[J]. 诊断学理论与实践, 2020, 19(05): 525-527.
[5]	王春花, 祁爽, 王敏. 原发性醛固酮增多症合并无痛性心肌梗死一例报告[J]. 诊断学理论与实践, 2020, 19(05): 528-530.
[6]	康健捷, 苏佩珣, 邓兵梅, 杨红军, 王卓才. 肾上腺腺瘤型原发性醛固酮增多症并发横纹肌溶解症一例[J]. 诊断学理论与实践, 2019, 18(05): 583-584.
[7]	蒋怡然, 王卫庆,. 中国原发性醛固酮增多症诊治专家共识解读[J]. 诊断学理论与实践, 2016, 15(04): 350-353.
[8]	宋琦, 杜联军, 张欢, 丁蓓, 潘自来, 陈克敏, 方文强,. 多层CT诊断原发性醛固酮增多症的评价[J]. 诊断学理论与实践, 2010, 9(04): 351-354.